Beaconlight Capital LLC Buys 39,928 Shares of QuidelOrtho Corporation $QDEL

Beaconlight Capital LLC increased its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 20.1% during the fourth quarter, Holdings Channel reports. The firm owned 239,049 shares of the company’s stock after acquiring an additional 39,928 shares during the period. QuidelOrtho makes up approximately 4.0% of Beaconlight Capital LLC’s investment portfolio, making the stock its 11th biggest position. Beaconlight Capital LLC’s holdings in QuidelOrtho were worth $6,827,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of QDEL. Global Retirement Partners LLC grew its position in QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after acquiring an additional 886 shares during the last quarter. Camelot Portfolios LLC bought a new position in QuidelOrtho in the fourth quarter valued at about $29,000. Hantz Financial Services Inc. grew its position in QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after acquiring an additional 362 shares during the last quarter. Larson Financial Group LLC grew its position in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after acquiring an additional 1,015 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new position in QuidelOrtho in the third quarter valued at about $63,000. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Stock Performance

NASDAQ:QDEL opened at $13.13 on Thursday. The stock has a market cap of $895.33 million, a P/E ratio of -0.74 and a beta of 0.77. The company has a current ratio of 1.43, a quick ratio of 0.80 and a debt-to-equity ratio of 1.33. The stock’s 50-day moving average is $12.86 and its 200-day moving average is $20.96. QuidelOrtho Corporation has a 1-year low of $9.92 and a 1-year high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.41). The firm had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The business’s revenue for the quarter was down 10.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities research analysts anticipate that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Citigroup decreased their target price on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. UBS Group reiterated a “neutral” rating and issued a $12.00 target price on shares of QuidelOrtho in a research report on Thursday, May 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Tuesday, April 21st. Wall Street Zen cut QuidelOrtho from a “buy” rating to a “hold” rating in a research report on Sunday, April 12th. Finally, Jefferies Financial Group cut QuidelOrtho from a “buy” rating to a “hold” rating and decreased their target price for the company from $35.00 to $12.50 in a research report on Thursday, May 7th. Four investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $14.88.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.